A STUDY TO EVALUATE THE USE OF PLACENTA PROTEIN 13 (PP13) IN THE FIRST TRIMESTER OF PREGNANCY AS A DIAGNOSTIC AIDING TOOL IN THE ASSESSMENT OF THE RISK FOR DEVELOPING PREECLAMPSIA IN WOMEN WITH LOW AND UNKNOWN RISK: